Systemic monoclonal antibodies against PD-1 and PD-L1 are widely used and have produced durable tumor regression and overall survival benefits in several solid and hematological cancers [41, 42]. This evidence concerns the gene CD274 and hematopoietic and lymphoid cell neoplasm.